CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blueprint Medicines, a company harnessing the understanding of the molecular blueprint of cancer to develop personalized, highly-selective cancer therapies, today announced that it was named as one of 2011’s Fierce 15 by FierceBiotech, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech’s ninth annual Fierce 15 selection.
“Blueprint is less than a year old, but to start a kinase inhibitor company with some of the developers of perhaps the most famous of all tyrosine kinase inhibitors, Gleevec®, deserves special notice in the biotech community,” says Ryan McBride, executive editor of FierceBiotech. “Hopefully the most exciting chapters have yet to be written about this firm.”
"Being honored as a Fierce 15 company further underscores our mission to enable a transformative shift in cancer treatment," said Chris Varma, chief executive officer of Blueprint. "We believe strongly in our ability to develop differentiated therapeutics that unlock the power of personalized medicine, and we are thankful to FierceBiotech for recognizing our approach with this designation."
An internationally recognized daily newsletter reaching more than 90,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick, authoritative briefing on the day's top stories. Every year FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.
The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. A complete list of “Fierce 15” companies – the online newsletter’s ninth annual selection – is available online at www.fiercebiotech.com.
About FierceBiotech
FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 90,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at http://www.fiercebiotech.com.
About Blueprint Medicines
Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. Using its powerful Insights-to-Validation™ Platform and proprietary chemical library, Blueprint Medicines is working to develop new therapeutic compounds and combination therapies that target the molecular aberrations that cause cancer and the emerging resistance mechanisms that make it increasingly difficult to treat. Founded in 2011 by a proven team of scientists and entrepreneurs with world-renowned expertise in the development of targeted cancer therapies, cancer genomics, and rational drug development, Blueprint Medicines is poised to realize the promise of the cancer data “revolution”: truly personalized therapies that improve outcomes and shift cancer to a manageable condition. For more information on Blueprint Medicines, please visit the company’s website at www.blueprintmedicines.com.
Gleevec® is a registered trademark of Novartis Pharmaceuticals Corporation.